Ashton Thomas Securities LLC Lowers Stake in Boston Scientific Corporation $BSX

Ashton Thomas Securities LLC lessened its stake in Boston Scientific Corporation (NYSE:BSX) by 1.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,499 shares of the medical equipment provider’s stock after selling 165 shares during the period. Ashton Thomas Securities LLC’s holdings in Boston Scientific were worth $1,128,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in BSX. Sound Income Strategies LLC grew its stake in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares in the last quarter. 1248 Management LLC bought a new position in shares of Boston Scientific during the 1st quarter worth $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific during the 1st quarter worth $27,000. Oliver Lagore Vanvalin Investment Group purchased a new position in shares of Boston Scientific during the second quarter valued at $37,000. Finally, Activest Wealth Management raised its holdings in shares of Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 373 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on BSX shares. Barclays raised their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Needham & Company LLC restated a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a report on Wednesday. BTIG Research lifted their price target on Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Leerink Partners upped their price objective on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and an average target price of $120.79.

Insider Activity at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last three months. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Trading Up 0.5%

Boston Scientific stock opened at $96.36 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a market cap of $142.78 billion, a PE ratio of 57.36, a price-to-earnings-growth ratio of 2.31 and a beta of 0.61. The stock has a 50-day moving average of $103.10 and a two-hundred day moving average of $102.06. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company’s revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.